MORGAN STANLEY PLC/PUT/ELI LILLY & CO/550/0.01/19.12.25 | Market Closed - Börse Stuttgart 12:19:34 11/07/2024 am IST | ||
| 0.176 EUR | -0.56% |
|
| Current month | -1.68% | ||
| 1 month | -16.98% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 10/24/10 | 0.176 | -0.56% |
| 09/24/09 | 0.177 | +1.72% |
| 08/24/08 | 0.174 | -8.42% |
| 05/24/05 | 0.19 | -5.00% |
| 04/24/04 | 0.2 | +0.50% |
Delayed Quote Börse Stuttgart
Last update July 11, 2024 at 12:19 am IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | Morgan Stanley |
| WKN | ME4GG0 |
| ISIN | DE000ME4GG04 |
| Date issued | 01/12/2023 |
| Strike | 550 $ |
| Maturity | 19/12/2025 (527 Days) |
| Parity | 100 : 1 |
| Emission price | 0.75 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.8 € |
|---|---|
| Lowest since issue | 0.168 € |
| Spread | 0.009 € |
| Spread % | 4.86% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
939.8
USD
Average target price
874.8
USD
Spread / Average Target
-6.92%
- Stock Market
- Warrants
- Warrant
